Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 3/20 | 0.34 |
| ▸ | GNRHR | P30968 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514518 | 0.85 | MAOB (0.41) | KMT2ANPC1MEN1RAB9ALMNA | |
| SCHEMBL3515441 | 0.82 | MEN1 (0.38) | KMT2AMEN1LMNASMN1; SMN2ALOX5 | |
| SCHEMBL3517570 | 0.78 | MEN1 (0.39) | KMT2AMEN1LMNASMN1; SMN2ELANE | |
| SCHEMBL3514327 | 0.77 | MEN1 (0.40) | KMT2ANPC1MEN1RAB9ALMNA | |
| SCHEMBL3515865 | 0.73 | MEN1 (0.42) | KMT2ANPC1MEN1RAB9ALMNA | |
| SCHEMBL3517897 | 0.70 | ALOX5 (0.41) | NPC1ALOX5 | |
| SCHEMBL3518051 | 0.69 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2ALOX5ELANE | |
| SCHEMBL3517498 | 0.69 | ELANE (0.45) | KMT2AMEN1ELANEMAOBKDM4E | |
| SCHEMBL3514525 | 0.68 | ALDH1A1 (0.55) | KMT2AMEN1LMNASMN1; SMN2ELANE | |
| SCHEMBL3516366 | 0.66 | MEN1 (0.41) | KMT2ANPC1MEN1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | ADORA1 1075/4885PDE5A 2933/4885GNRHR 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.